Novo Nordisk says generic Ozempic, Wegovy will slow sales in ...
Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.
globalnews.caHere is the latest on generic semaglutide in Canada based on recent news and Health Canada releases.
Key updates
- Health Canada approved the first generic semaglutide injection in Canada, the active ingredient in Ozempic/Wegovy, marking the country as the first G7 nation to authorize a generic version. This initial approval involved Dr. Reddy’s Laboratories (India) for a once-weekly diabetes indication in adults.[1][5]
- A few days later, Health Canada approved a second generic semaglutide injection, this time from Canadian company Apotex, further expanding access. Canada remains the first G7 country to have multiple generic semaglutide products authorized.[2][3]
- Health Canada notes that seven additional generic semaglutide submissions are under review, with decisions anticipated in the weeks and months ahead. Availability may vary by region as products move through distribution channels to pharmacies nationwide.[3][4]
- Canadian press and obesity-health groups emphasize that the approvals aim to improve access and affordability, while regulators continue to monitor safety and effectiveness post-market.[4][6][10]
What this means for you (Prague-based, with Canada interest)
- If you’re considering generic semaglutide in Canada, expect multiple manufacturers to offer similar formulations once supply chains are fully in place, potentially lowering out-of-pocket costs compared with brand-name Ozempic/Wegovy. Health Canada’s stated approach is safety, efficacy, and quality parity for generics, with continued safety monitoring after approval.[5][1][3]
- Availability varies by region and pharmacy, so check with local Canadian pharmacies or your healthcare provider for the latest stock and eligibility, especially if you rely on coverage or reimbursement programs.[4]
Helpful context and sources
- Health Canada’s announcements confirm the first generic approval (Dr. Reddy’s) and the subsequent second approval (Apotex), and note ongoing reviews of other submissions.[2][3][5]
- Canadian media coverage highlights that Canada is leading the G7 in generic semaglutide approvals and discusses potential price and access implications for patients.[1][4]
- International outlets and obesity-health organizations discuss access, coverage considerations, and ongoing regulatory activity related to generic semaglutide in Canada.[6][10]
Would you like a brief timeline of the approvals with dates, or a quick summary of expected pricing considerations and how to check availability in Canada? I can also pull together a concise list of Canada-wide resources (Health Canada pages, provincial coverage hints, and patient-assistance programs) if you’re planning a follow-up.